Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Moderna (MRNA – Research Report) and Lantheus (LNTH – Research Report).
Moderna (MRNA)
In a report released today, Tyler Van Buren from TD Cowen maintained a Hold rating on Moderna, with a price target of $75.00. The company’s shares closed last Thursday at $99.65.
According to TipRanks.com, Buren is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Moderna with a $131.38 average price target, representing a 43.0% upside. In a report issued on February 15, Bank of America Securities also maintained a Hold rating on the stock with a $120.00 price target.
See today’s best-performing stocks on TipRanks >>
Lantheus (LNTH)
TD Cowen analyst Tara Bancroft maintained a Buy rating on Lantheus today and set a price target of $83.00. The company’s shares closed last Thursday at $63.95.
According to TipRanks.com, Bancroft is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Lantheus with a $96.63 average price target, which is a 53.4% upside from current levels. In a report issued on February 14, Leerink Partners also maintained a Buy rating on the stock with a $96.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MRNA:
